表紙
市場調査レポート

血管新生緑内障:世界の治験動向

Neovascular Glaucoma Global Clinical Trials Review, H1, 2015

発行 GlobalData 商品コード 324944
出版日 ページ情報 英文 66 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
血管新生緑内障:世界の治験動向 Neovascular Glaucoma Global Clinical Trials Review, H1, 2015
出版日: 2015年01月21日 ページ情報: 英文 66 Pages
概要

当レポートでは、血管新生緑内障に関する臨床研究の最新動向について調査し、地域・進捗状況・フェーズ (相) ・募集状況別の実施件数や、代表的なスポンサー、開発中の治療薬の情報、世界各国の主要企業・機関での進行状況、有望な薬剤の比較といった情報を盛り込んでお届けします。

イントロダクション

  • 血管新生緑内障
  • レポートガイダンス

地域別の治験件数

  • 国別の治験件数および平均参加者数
    • アジア太平洋地域の主要国における治験件数
    • 欧州の主要国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要国における治験件数
    • 中南米の主要国における治験件数

G7諸国での治験件数:眼科の治験における血管新生緑内障の割合

G7諸国での治験件数:相 (フェーズ) 別

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:眼科の治験における血管新生緑内障の割合

E7諸国での治験件数:相 (フェーズ) 別

E7諸国での治験件数:進捗状況別

相 (フェーズ) 別の治験件数

  • 進行中の治験:相別

進捗状況別の治験件数

治験の目標の達成状況

未完了の治験件数:血管新生緑内障

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

  • 血管新生緑内障の治療薬の治験に携わっている主要企業

有望な薬剤

治験のプロファイル

  • 代表的企業の治験の概況
    • Gene Signal International SA
    • ODIN Biotech Partners, LLC
  • 主要な研究機関/政府機関/病院の治験の概要
    • 熊本大学
    • Federal University of Sao Paulo
    • University of Illinois
    • 島根大学
    • Universidade Federal de Uberlandia
    • Hong Kong Eye Hospital
    • University of Lubeck
    • Faculty of Medicine Siriraj Hospital, Mahidol University
    • Shahid Beheshti University of Medical Sciences
    • Cairo University

5つの代表的な治験のプロファイル

付録

目次
Product Code: GDHC2530CTIDB

GlobalData's clinical trial report, "Neovascular Glaucoma Global Clinical Trials Review, H1, 2015" provides data on the Neovascular Glaucoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neovascular Glaucoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neovascular Glaucoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Neovascular Glaucoma
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Neovascular Glaucoma to Ophthalmology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Neovascular Glaucoma to Ophthalmology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Neovascular Glaucoma
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Neovascular Glaucoma Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Gene Signal International SA
      • Clinical Trial Overview of Gene Signal International SA
      • ODIN Biotech Partners, LLC
      • Clinical Trial Overview of ODIN Biotech Partners, LLC
    • Clinical Trial Overview of Top Institutes / Government
      • Kumamoto University
      • Clinical Trial Overview of Kumamoto University
      • Federal University of Sao Paulo
      • Clinical Trial Overview of Federal University of Sao Paulo
      • University of Illinois
      • Clinical Trial Overview of University of Illinois
      • Shimane University
      • Clinical Trial Overview of Shimane University
      • Universidade Federal de Uberlandia
      • Clinical Trial Overview of Universidade Federal de Uberlandia
      • Hong Kong Eye Hospital
      • Clinical Trial Overview of Hong Kong Eye Hospital
      • University of Lubeck
      • Clinical Trial Overview of University of Lubeck
      • Faculty of Medicine Siriraj Hospital, Mahidol University
      • Clinical Trial Overview of Faculty of Medicine Siriraj Hospital, Mahidol University
      • Shahid Beheshti University of Medical Sciences
      • Clinical Trial Overview of Shahid Beheshti University of Medical Sciences
      • Cairo University
      • Clinical Trial Overview of Cairo University
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials by Region, 2015*
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Europe, Top Countries, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials, North America, Top Countries, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Central and South America, Top Countries, 2015*
  • Proportion of Neovascular Glaucoma to Ophthalmology Clinical Trials, G7 Countries (%), 2015*
  • Neovascular Glaucoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Neovascular Glaucoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Proportion of Neovascular Glaucoma to Ophthalmology Clinical Trials, E7 Countries (%), 2015*
  • Neovascular Glaucoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2015*
  • Neovascular Glaucoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015*
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials by Phase, 2015*
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials In Progress by Phase 2015*
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Neovascular Glaucoma Therapeutics, Global, Withdrawn Clinical Trials, 2015*
  • Neovascular Glaucoma Therapeutics, Global, Terminated Clinical Trials, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Neovascular Glaucoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Gene Signal International SA, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials Market, Global, Clinical Trials by ODIN Biotech Partners, LLC, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Kumamoto University, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Federal University of Sao Paulo, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Illinois, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Shimane University, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Universidade Federal de Uberlandia, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Hong Kong Eye Hospital, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Lubeck, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Faculty of Medicine Siriraj Hospital, Mahidol University, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Shahid Beheshti University of Medical Sciences, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Cairo University, 2015*

List of Figures

  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials by Region (%), 2015*
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Europe, Top Countries (%), 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015*
  • Proportion of Neovascular Glaucoma to Ophthalmology Clinical Trials, G7 Countries (%), 2015*
  • Neovascular Glaucoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Neovascular Glaucoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Proportion of Neovascular Glaucoma to Ophthalmology Clinical Trials, E7 Countries (%), 2015*
  • Neovascular Glaucoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2015*
  • Neovascular Glaucoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015*
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials by Phase (%), 2015*
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2015*
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Neovascular Glaucoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*
  • GlobalData Methodology
Back to Top